Instead of indiscriminately targeting skeletal bone matrix or inhibiting the function of OCs with different drugs, we explored a treatment paradigm that uses the same drug (TC) and radiopharmaceutical ([18F]FDG) RaST to deplete both tumor-associated OCs and disrupt the MM-OC interaction during therapy. Here, BGLAP is linked to neoplasm.